Highest-materiality recent filing
Genasys Q3 FY2026 revenue down 26% to $7.3M; net loss narrows to $4.7M
Revenue $7.3M vs $9.9M YoY; gross margin 57.1% vs 26.3% on higher software mix.
Genasys prelim Q3 revenue $7.0-7.5M; backlog $69M; expects record Q4
Preliminary Q3 revenue $7.0-7.5M; gross margin 55-58%; adjusted EBITDA loss ($3.0)-($3.3)M.
Genasys extends $15.2M term loan maturity to July 2027; adds monthly payments, 20% minimum return
Maturity extended from July 13, 2026 to July 13, 2027; interest rate remains 3-month SOFR + 5%.
Genasys enters $4.3M unsecured term loan at 18% with Maran Partners
Loan of $4.3M at 18% annual interest, maturing September 14, 2026.
Genasys reports Q2 net income $0.7M, revenue $15.5M (+124% YoY), gross margin 63%
Revenue $15.5M vs $6.9M YoY (+124%); gross margin 63.3% vs 37.7%.
Genasys appoints Larry Hagenbuch to board, will chair Audit Committee
Elected Larry Hagenbuch as director and Audit Committee chair, effective March 26, 2026.
All five director nominees elected; Richard S. Danforth received 13.1M for, 2.2M withheld.
Genasys Q1 FY2026 revenue $17.1M (+146% YoY), narrows net loss to $0.8M
Revenue $17.1M, up 145.9% from $6.9M YoY; gross margin 48.0% vs 45.8%.
Base salary $490,000; target cash bonus equal to 100% of base salary with max $784,000.
Genasys promotes Cassandra Hernandez-Monteon to permanent CFO, Treasurer, and Secretary
Interim CFO since July 1, 2025, appointed permanently effective Dec 24, 2025.
Genasys enters amended cooperation agreement with Nicoya Capital, nominates five directors for 2026
Nicoya Capital (affiliate of director Malhotra) extends standstill; Genasys nominates Danforth, Dodd, Fugate, Malhotra, Schmeiser for 2026 board.
Genasys Chairman Richard Osgood III to step down from board, join advisory board
Osgood notified board he will not stand for re-election at the 2026 annual meeting.
Genasys Q4 revenue surges 152.6% to $17.0M; returns to positive operating income and adjusted EBITDA
Q4 GAAP operating income of $1.3M vs ($7.1M) loss a year ago; adjusted EBITDA of $2.4M vs ($6.0M).
Genasys Q3 revenue up 38% to $9.9M; net loss per share improves to ($0.14); cash drops to $5.5M
Revenue $9.9M (+38% YoY); GAAP net loss ($6.5M) or ($0.14) per share vs ($0.15) prior year.
Genasys CFO Dennis Klahn retires; Cassandra Hernandez-Monteon named interim CFO
Dennis Klahn retired as CFO, Treasurer and Secretary effective July 1, 2025.
Genasys Q2 revenue up 21% to $6.9M, net loss narrows; CFO Klahn to retire
Revenue $6.9M (+21% YoY); GAAP net loss ($6.1M) vs ($7.0M) prior year; EPS ($0.14).
Genasys stockholders approve 2025 Equity Incentive Plan with 6M share pool
2025 Equity Plan approved with 8,327,901 for, 6,690,236 against, 13,696,608 broker non-votes.
Genasys Q1 revenue $6.9M (+59% YoY); net loss narrows to $4.1M
Revenue $6.9M vs $4.4M YoY; software revenue +63.5%, hardware +57.1%.
Genasys appoints R. Rimmy Malhotra to board under cooperation agreement with Nicoya Capital
Board expanded from 6 to 7; Malhotra appointed January 15, 2025, and to audit committee.
Genasys reports Q4 revenue down 37% YoY; FY2024 net loss $31.7M
Revenue $6.7M in Q4 ($10.7M YoY); full-year $24.0M ($46.7M YoY).
Genasys Q3 revenue halved to $7.2M; net loss widens to $6.7M; $75M Puerto Rico project approved
Revenue of $7.2M versus $14.3M in Q3 2023; GAAP net loss of ($6.7)M vs ($1.4)M; EPS ($0.15) vs ($0.04).
Genasys appoints Mark Culhane to Board as Audit Committee Chair; Seymour resigns
Mark Culhane appointed to Board effective July 10, 2024; will chair Audit Committee.
Director Caltha Seymour resigns from Genasys Board effective July 1, 2024
Caltha Seymour resigned from Genasys Board effective July 1, 2024, due to increasing demands of her employment.
Director Scott Anchin resigns from Genasys Board effective May 31, 2024
Scott Anchin resigned due to new employment requiring him to leave outside board roles.
Revenue $5.7M vs $11.2M YoY; GAAP net loss $6.9M ($0.16 diluted loss per share).
Genasys shareholders elect all five director nominees and approve say-on-pay at annual meeting
All five director nominees elected: Anchin, Danforth, Lee, Osgood, Seymour.
Genasys Q1 revenue $4.4M down 58% YoY; Puerto Rico dam contract worth $60-$70M
Revenue $4.4M (-58.4% YoY); GAAP net loss ($6.7M) vs ($3.5M) YoY; EPS ($0.15).
Genasys Q1 revenue down 58% to $4.4M, net loss per share ($0.15)
Revenue $4.4M, down 58.4% YoY; GAAP net loss ($6.7M), EPS ($0.15) vs ($0.10) prior year.
Genasys FY2023 revenue down 13.5%; Q4 loss widens; software ARR grows 43%
Q4 revenue $10.7M vs $16.0M YoY (-33%); FY revenue $46.7M vs $54.0M (-13.5%).
Genasys completes Evertel acquisition and closes $11.5M public offering of 5.75M shares at $2.00
Acquired Evertel Technologies, a cross-agency collaboration platform for public safety; issued 986,486 shares as partial payment.
Genasys prices $10M public offering of 5M shares at $2.00/share
5,000,000 shares priced at $2.00 each for gross proceeds of $10M.
Genasys signs definitive agreement to acquire Evertel for ~$5.8M in cash/stock
Total consideration of $5.8 million, ~75% stock and ~25% cash, subject to customary adjustments.
Genasys cuts FY2023 revenue outlook to 15% below prior year; Q4 rev at least $10M
Full year revenues expected 15% below prior year; Q4 2023 revenue at least $10M, down from prior outlook of ~5% sequential decline.
Genasys Q3 revenue flat, GAAP loss widens to ($0.04)/share; guides Q4 down 5% sequentially
Revenue $14.3M (+0.8% YoY); GAAP operating loss ($1.5M) vs ($0.6M) YoY.
Genasys Q2 revenue falls 14.8% YoY to $11.2M; guides FY2023 down slightly
GAAP net loss per share ($0.09) vs ($0.01) prior year; adjusted EBITDA loss ($2.3M) vs profit $0.9M.
Genasys reports 2023 annual meeting results; all director nominees and proposals pass
Elected five director nominees: Anchin, Danforth, Osgood, Lee, Seymour each received >13.6M votes for.
Genasys Q1 revenue $10.5M (-2% YoY), net loss $3.5M; SaaS bookings record $6.1M
Revenue $10.5M (-2% YoY); net loss $3.5M ($0.10 per share) vs loss $1.3M ($0.04) last year.
Genasys reports FY2022 revenue $54M (+15%), net loss $16.2M, CEO gets amended agreement
FY2022 revenue $54.0M (+15% YoY); net loss $16.2M ($0.44/share) vs net income $0.7M in FY2021.
Genasys Q3 revenue up 12% to $14.2M; net loss $0.6M; backlog $30M
Revenue of $14.2M, up 12% YoY; gross margin 46.5% down 440 bps on higher component costs.
Genasys presents at LD Micro conference with updated investor presentation
No specific financial or operational updates disclosed in the filing.
Genasys Q2 revenue up 17% to $13.2M; backlog jumps 73% to $23.9M
Net loss of $0.5M ($0.01/diluted share) vs net income of $0.3M a year ago.
Genasys annual meeting elects all six director nominees; auditor ratified
Scott L. Anchin, Laura M. Clague, Richard S. Danforth, Richard H. Osgood III, Susan Lee, Caltha Seymour elected as directors.
Revenue $10.7M, up 33% YoY; gross margin 45.9% vs 46.1% prior year.
Genasys FY2021 revenue record $47M, up 9%; EPS $0.02 vs $0.35; backlog $36.1M, +217%
Q4 revenue $15.0M (+8% YoY); net income $0.8M ($0.02 diluted) vs $9.4M ($0.27) in prior year quarter which included $6.4M tax benefit.
Daniel McCollum resigns from Genasys Board, joins Strategic Advisory Board
Resignation effective Nov 11, 2021; not related to any disagreement with the Company.
Genasys announces Coburn to step down as Board Chairman, become Chair of Strategic Advisory Board
General John G. Coburn resigns from Board and Chairman role effective Nov 1, 2021; becomes Chairman Emeritus and Chair of Strategic Advisory Board.
Genasys appoints Susan Lee and Caltha Seymour to Board of Directors
Appointment effective September 1, 2021; both are independent directors.
Genasys Q3 revenue $12.6M (+6%); record bookings $44.3M; net income $0.3M vs $1.5M
Revenue $12.6M (+6% YoY), net income $0.3M ($0.01 EPS) vs $1.5M prior year.
On May 13, 2025, Dennis D. Klahn, Chief Financial Officer of the Company, informed the Company that he intends to retire from all positions he holds with the Company and its subsidiaries during the fiscal fourth quarter of 2025.
On July 10, 2024, the Company announced the appointment of Mark Culhane to the Board of Directors
On July 1, 2024, Genasys Inc. (the “Company”) received notice from Caltha Seymour of her resignation from the Board of Directors of the Company effective immediately due to increasing demands of her employment.
On May 20, 2024, the Company received written notice from Scott L. Anchin of his resignation from the Board of Directors of the Company (the “Board”), effective May 31, 2024, due to the requirements of his new employment.
the Company announced the appointment of Bill Dodd and Craig Fugate to the Board of Directors (the “Board”) of the Company effective June 1, 2024
the Company announced the appointment of Bill Dodd and Craig Fugate to the Board of Directors (the “Board”) of the Company effective June 1, 2024
On May 6, 2022, the Company received notice from Laura M. Clague of her retirement from the Board of Directors of Genasys Inc. (the "Company") effective June 30, 2022.
On November 11, 2021, the Company received written notice from Daniel H. McCollum of his resignation from the Board of Directors of the Company (the “Board”) and from all Board committees on which he serves.
Concurrent with his resignation from the Company’s Board, Mr. McCollum and the Company entered into a Board Adviser Agreement (the “Adviser Agreement”), which is effective as of Mr. McCollum’s resignation. Pursuant to the Adviser Agreement, Mr. McCollum will join the Company’s Strategic Advisory Board
Pursuant to the Adviser Agreement, General Coburn will become the Chair of the Company’s Strategic Advisory Board.
On October 22, 2021, the Company received written notice from General John G. Coburn of his resignation from the Board of Directors of the Company (the “Board”), effective November 1, 2021.
On August 18, 2021, Genasys Inc. (the “Company”) announced the appointment of Susan Lee and Caltha Seymour to the Board of Directors (the “Board”) of the Company effective September 1, 2021
Max materiality 0.85 · Median 0.65 · Most common event earnings